RxDoctor Payments Data

Britten Young, MD

Cardiovascular Disease · Nashville, TNNPI 1659588929

Payments from drug & device makers

$887in general payments, 2019–2025

Across 42 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$272
  • Argon Medical Devices, Inc.$232
  • Amgen$170
  • E.r. Squibb & Sons, L.L.C.$94
  • Boehringer Ingelheim$23
  • Heartflow, Inc.$22
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$887 in reported general payments places this provider in the 35th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$117,707
Medicare patients
994
Services billed
2,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$359,482
Repatha SureclickEvolocumab269$179,437
XareltoRivaroxaban53$56,126
EntrestoSacubitril/Valsartan37$48,904
Ranolazine ErRanolazine109$22,908
Repatha PushtronexEvolocumab28$17,387
Ezetimibe437$14,393
FarxigaDapagliflozin Propanediol12$7,929
Rosuvastatin Calcium610$7,713
VascepaIcosapent Ethyl11$6,540
Metoprolol Succinate394$6,383
Atorvastatin Calcium487$6,141
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$4,611
Icosapent Ethyl13$2,849
Amiodarone Hcl53$2,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$56,12653 claims
NovartisEntresto$272$48,90437 claims
AstraZenecaFarxiga$14$7,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →